U.S. markets closed

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4147+0.0102 (+2.52%)
At close: 04:00PM EDT
0.4199 +0.01 (+1.25%)
After hours: 05:18PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close0.4045
Bid0.4070 x 900
Ask0.4200 x 1400
Day's Range0.4050 - 0.4260
52 Week Range0.3820 - 3.6400
Avg. Volume3,891,810
Market Cap56.8M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-1.0800
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for UBX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Unity Biotechnology, Inc.
    Technical Assessment: Neutral in the Intermediate-TermInterest rates across the entire curve went somewhat parabolic in August. The U.S. Dollar Index continued its very steep ascent. The Federal Reserve is maintaining its hawkish stance based on its latest fed funds targets. As well, the Fed "finally" is getting its quantitative tightening (QT) in gear, which pulls liquidity out of the marketplace. Oh, and stock investors have been losing massive amounts of money. One might believe the economy is falling off a cliff. At least gasoline prices have crashed.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration

    Enrollment of 51 patients exceeds target by ~10% due to high interest in the study 16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the ENVISION study, its Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degen

  • InvestorPlace

    The Three Best Anti-Aging Stocks to Buy in September

    Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth companies. As a result, the Nasdaq Biotechnology Index and SPDR S&P Biotech ETF (NYSEARCA:XBI) have fallen 16.5% and 23.5%, year to date (YTD), respectively. Despite the market sell-off, innovative medical technology companies and anti-aging stocks are subjects of interest on Wall S

  • GlobeNewswire

    UNITY Biotechnology to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September. Citi 17th Annual BioPharma Conference Format: One-on-one investor meetings Date: September 6 – 8, 2022Location: Four Seasons Hotel Boston, Massachusetts H.C. Wainwright 24th A